Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma Plc (RPRX) drives biopharmaceutical innovation by funding therapies through strategic royalty acquisitions. This dedicated news hub provides investors with essential updates on the company's financial developments and industry impact.
Access real-time announcements including quarterly earnings, royalty agreement expansions, and regulatory milestones. Our curated feed helps stakeholders track RPRX's role in advancing treatments across oncology, immunology, and rare diseases.
Discover how Royalty Pharma's unique business model supports drug development while maintaining revenue stability. The page features verified updates on portfolio additions, strategic collaborations, and market analyses relevant to RPRX's position in healthcare finance.
Bookmark this page for streamlined access to Royalty Pharma's official communications and third-party analyses. Check regularly for insights into how the company continues shaping biopharma funding through calculated royalty investments.
Ferring Pharmaceuticals has received FDA approval for a new drug product manufacturing facility in Parsippany, NJ, for ADSTILADRIN®, their intravesical non-replicating gene therapy. This milestone triggers a final $200 million payment from Royalty Pharma (RPRX).
The new 12,000-square-foot facility becomes the company's third manufacturing site for ADSTILADRIN, joining existing operations in Kuopio, Finland. The state-of-the-art facility features renewable energy solutions and specialized modern technology to ensure sustainable supply for anticipated global demand.
ADSTILADRIN is the first FDA-approved intravesical non-replicating gene therapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Bladder cancer ranks as the sixth most diagnosed cancer in the United States, with most patients diagnosed with non-muscle invasive disease.
Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend declaration for Q2 2025. The company's board of directors has approved a dividend payment of $0.22 per Class A ordinary share. The dividend is scheduled to be distributed on June 10, 2025, to shareholders who are recorded in the company's books at the close of business on May 16, 2025.
Royalty Pharma (Nasdaq: RPRX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time on the same day.
Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
Royalty Pharma (RPRX) has appointed Dr. Vlad Coric to its Board of Directors, effective immediately. Dr. Coric, currently Chairman and CEO of Biohaven, brings over 20 years of drug discovery and clinical development experience from Yale School of Medicine and Bristol-Myers Squibb.
Under his leadership at Biohaven, Dr. Coric achieved significant milestones including:
- FDA approval and launch of Nurtec ODT for migraine treatment
- NDA filing for zavegepant, the first intranasal CGRP antagonist for migraine
- Led Biohaven's growth from founding through its $13 billion sale to Pfizer in May 2022
His expertise spans multiple therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. Dr. Coric completed his medical education at Wake Forest University and postdoctoral training at Yale School of Medicine.
Royalty Pharma (Nasdaq: RPRX) has announced plans to host an Investor Day on September 11, 2025, in New York City. The event will commence at 8:30 a.m. ET.
During the event, senior executives will present updates on the company's strategy for creating shareholder value by leveraging its distinctive business model and capabilities in the biopharma innovation funding market. The presentation will include interactive Q&A sessions.
Investors can access the live webcast through the 'Investors' section of Royalty Pharma's website, where it will remain archived for at least thirty days.
Royalty Pharma (Nasdaq: RPRX) has announced its upcoming participation in TD Cowen's 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for March 4, 2025, at 2:30 p.m. ET.
Interested parties can access the webcast through the company's 'Events' page on their investor relations website. The recording will remain available for a minimum of thirty days following the presentation.
Royalty Pharma (RPRX) has entered into an R&D funding agreement with Biogen, committing up to $250 million to support the development of litifilimab, a first-in-class investigational drug for lupus treatment. The funding will be provided over six quarters in exchange for regulatory milestones and mid-single digit royalties on worldwide sales.
Litifilimab is currently in Phase 3 trials for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), with results expected between 2026 and 2027. The drug has shown proof of concept and a generally well-tolerated safety profile in both conditions, with results published in the New England Journal of Medicine. SLE affects over 3 million patients worldwide, and litifilimab could potentially become the first targeted biologic specifically approved for CLE treatment.
Royalty Pharma (RPRX) reported strong financial results for Q4 and FY 2024, with Portfolio Receipts reaching $742 million in Q4 and $2,801 million for FY 2024. The company achieved 12% growth in Royalty Receipts in Q4 and 13% for FY 2024, driven by strong performance from products including Evrysdi, CF franchise, Trelegy, and Tremfya.
Key highlights include $2.8 billion in capital deployment in 2024, with royalties acquired on eight new therapies. The company provided 2025 guidance projecting Portfolio Receipts between $2,900-$3,050 million, representing 4-9% growth. Net cash from operations was $743 million in Q4 and $2,769 million for FY 2024.
In January 2025, RPRX announced a new $3 billion share repurchase program, with plans to repurchase $2 billion in 2025. The company also announced the acquisition of its external manager, expected to generate over $100 million in cash savings by 2026.
Royalty Pharma (RPRX) has completed the monetization of MorphoSys Development Funding Bonds, receiving $511 million in upfront cash. Combined with previous payments, this brings total proceeds to $530 million on their original $300 million investment made in September 2022.
The monetization was executed at a 5.35% discount rate, following Novartis' acquisition of MorphoSys. Prior to this transaction, RPRX received two quarterly payments of $9.7 million each in Q4 2024 and January 2025. The company plans to reinvest the proceeds into share repurchases and new royalty acquisitions as part of their updated capital allocation strategy.
The Development Funding Bonds were part of a larger 2021 strategic partnership where RPRX provided up to $2.025 billion for MorphoSys' acquisition of Constellation Pharmaceuticals, including royalties on Tremfya and other development-stage assets.
Royalty Pharma (Nasdaq: RPRX) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 11, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the conference call details and live webcast through the company's website investor relations section. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
